
Biotech Investor @ The Column Group | ChemBio PhD from @GestwickiLab @UCSF | Mass spec and bad pun enthusiast. Occasional cycling / sports tweets. Views my own.
San Francisco, CA
Joined July 2019
- Tweets334
- Following653
- Followers403
- Likes2.3K
Pinned Tweet
I’m super excited to share a preprint of my graduate work, out now on @biorxivpreprint! If you are interested in E3 ligases, chemical biology, or proteostasis, this one’s for you! Check it out at doi.org/10.1101/2023.07.17.5…, or see below for a summary 👇
I'm excited to announce that our team has been working closely with @Anthropic to develop new skills and workflows for drug development. We believe these tools can accelerate & improve our process of company creation, helping focus limited resources on the highest impact projects
Over the past few months, Anthropic scientists have engaged in deep research partnerships with six organizations developing new medicines. We've also begun drug discovery efforts of our own.
In doing so, we’ve learned much more about how Claude can support the many stages of drug development.
In this blog post, we share some early results from these efforts, and describe how this work fits in with our wider ambitions in the life sciences.
anthropic.com/research/early…
The long-term goal is to reduce the capital required to test new ideas in the clinic. In a world increasingly focused on incremental innovation, we hope that efficiency can be a lever to re-incentivize investment in truly novel hypotheses.
These are the projects with the highest risk but also the highest potential reward for patients. Looking forward to continuing to work with @nc_frey, @an1lam, @kalyanmpalepu, and the entire team!
Matt Callahan retweeted
Surprise 1: Anthropic acquired a one-person biotech
.
.
.
Surprise 2: that person is me
Surprise 3: I’m here to tell you all about it
Yes, this is what you think it is; after 6 yrs of increasingly loose anonymity: the Professor Oak reveal post
…and yes, it has gotten so boring around here that I’m literally doxxing myself to spice up the timeline
-------
Ok, allow me to introduce myself. My name is Cody Tranbarger. I mostly tweet, but occasionally find time to dabble in drug dev & starting/building biotechs. My past lives span the VC, crossover, startup continuum; Prof Oak has been my way of keeping a digital foot in those worlds, despite having my physical feet planted elsewhere.
The past 18 mo, ‘elsewhere’ was Mithril Medicine, a co. I founded to develop bsAbs for LAMA2-CMD & other ECM-related genetic diseases.
Mithril was born out of hands-on building with @MikeNGladstone, @JasonPaulRhodes, @LifeSciVC, & team @atlasventure. Somehow, I made enough half-decent calls along the way (even a broken clock is right twice a day, eh?) to convince them Mithril/I warranted a small seed. While I can hardly rationalize such an outrageously cavalier bet, I’m grateful for it, & I'd partner with Atlas again in a heartbeat.
In typical AV fashion, Mithril’s primordial form was virtual, decentralized, & ultra-lean. This stage tends to be short-lived, but for Mithril, it worked surprisingly well, for surprisingly long, thanks in part to the rapid maturation of the AI tools I used liberally.
Eventually, Mithril became a bit of an experiment itself - to find the upper bound of how far it could scale as a single operator + a bunch of Claude (+ a stellar bench of part-time consultants).
In parallel, I started spending time with @nc_frey, @an1lam, & @CoefficientBio team; and promptly experienced, for the 1st time, AI at the frontier. Soon thereafter, Mithril stopped looking like an experiment, & started looking like a preview of an entirely new operating model.
From that spark came “Pipeline-in-a-Person.” The idea immediately resonated when we shared it here back in April; and it was central to the shared vision that led to Anthropic’s acquisition of Mithril, & my joining the team.
Why join Anthropic? Three reasons.
(1) For Mithril, the programs continue, with more resources & infrastructure behind them, and as much Claude as I can put to work.
(2) For me, the chance to start several more programs, & find out how many one person can actually run in parallel - an almost unprecedented luxury for a curious drug hunter.
(3) For our mission, a path to institutionalize & scale this new way of working, then put it in the hands of all of biopharma, all over the world - which, candidly, I find the most energizing.
Will AI x Bio cure diseases? Unequivocally yes, imo… but not by the route that gets the most airtime. Rather than timeline acceleration & compression, I see orchestration & parallelization as today's low-hanging fruit.
Most drug hunters see a handful of go/no-go calls in a career, & spend entirely too much of the rest trading emails (my inbox can attest).
Give them the bandwidth to run several programs at once, and the time to focus on scientific judgment, and I’m willing to bet they’ll make better calls. And at scale, better calls translate to more drugs, higher hit rates, broader patient impact, & likely, a disease or 10 or 100 cured. I couldn't be more excited to build toward that future @AnthropicAI.
Finally, a heartfelt thank you to BioTwitter/X. The end of anonymity is bittersweet, but if anyone’s earned a proper introduction, you all have.
It’s difficult to overstate how much this app has done for me: a decade of education, plenty of friends, many job opportunities, several mentors, a few investors, even a co-founder (fmr). It was the generosity of this community that inspired me to start posting 6 years ago, after just as many years lurking. I hope I’ve been able to pay it forward, in my own small way.
But, to be clear, Prof Oak isn’t going anywhere. Same beat, same themes, and now, a front-row seat to drug development at the frontier. Stay tuned for dispatches from the trenches; and remember...
Gotta Cure 'Em All
Matt Callahan retweeted
The best way to identify and work through the bottlenecks of drug development is to get deeply involved in real drug programs, across many different therapeutic areas and stages of development. Over the past several months, our scientists have engaged in deep research partnerships with six organizations developing new medicines: The Column Group, Generate Biomedicines, BigHat Biosciences, Divergence Labs, Enveda, and Bristol Myers Squibb. We’ve also begun our own drug discovery efforts through the acquisition of Mithril Medicine, a single-person biotech company co-founded by @atlasventure.
Today we’re sharing early progress in accelerating drug discovery from these research collaborations. With Claude, we are streamlining operations and working to derisk novel targets with TCG, redesigning lab protocols with BigHat, designing CAR-T cell therapies with Generate, and multi-specific therapeutic antibodies with Divergence, drafting regulatory filings with Enveda, and supporting portfolio-level decision making with BMS. Our early collaborations span pre-clinical and clinical work on potential treatments for cancer, allergies, rare genetic diseases including forms of childhood muscular dystrophy, and more.
My team has been working with @Prof_Oak_ , founder of Mithril Medicine, for the past year. Jason Rhodes, General Partner @atlasventure and Chairman of the Mithril Board said this about Mithril: “We prioritized LAMA2-Related Congenital Muscular Dystrophy (LAMA2-RD) as the lead indication, in part, because of the enormous unmet need. These patients present with the disease at birth, spend their lives in wheelchairs and on ventilators, and rarely live past their mid-twenties; yet no therapy is available, and few are in active development. We believed Mithril would be the company to change that.” Anthropic acquired Mithril and we are pushing the frontier of how a single skilled operator, with Claude, can run an entire pipeline of drugs.
We’re working with these teams to show how AI can assist drug developers at many stages of the process already, and to prioritize improvements to our models based on the benchmarks we’re building with collaborators. Our blog includes links to technical reports written with our partners: anthropic.com/research/early…
Presented at #ASCO26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM
@ASCO

ALT Graph from a study published in the New England Journal of Medicine on daraxonrasib versus chemotherapy for metastatic pancreatic cancer. The x-axis represents months, and the y-axis shows the percentage of patients alive. Two lines indicate survival rates: daraxonrasib (blue) and chemotherapy (gray). The bottom section lists patients at risk over time. Title and journal logo are included.
Matt Callahan retweeted
Today we report that an engineered skin bacterium, swabbed gently on the head of a mouse, can unleash a potent antibody response against a pathogen. Could lead to topical vaccines that are applied in a cream. @DjenetBousbaine led the charge... @Nature 1/55
Matt Callahan retweeted
How to pick a problem. Today in @CellCellPress. 1/53
cell.com/cell/fulltext/S0092…
Matt Callahan retweeted
As it turns out, the secretion channel Sec61αβγ has a fourth subunit, RAMP4—long overlooked because it falls off in detergent. It holds the pore open and completes the lumenal funnel. This plus exciting structures of TRAP, uL22, & more are now online: biorxiv.org/content/10.1101/…
Matt Callahan retweeted
FTC vs Sanofi/Maze: very bad precedent for gov't overreach. And bad in general for patients in all disease areas
FTC continues to create friction in the deal mkt that is so vital to our collaborative biotech ecosystem reliant on external innovation
globenewswire.com/news-relea…
Matt Callahan retweeted
We’ve always wondered if there was something beyond CRISPR for genome editing. We now report that animals, plants, fungi and viruses have troves of programmable nucleases capable of efficient gene editing in human cells
An update on our Fanzor work!
science.org/doi/10.1126/scia… 1/7
Yesterday I defended my thesis in front of many dear friends and family. After so many years of hard work, it felt amazing to share this moment with them. Proud to finally say that I’m #PhDone!
Matt Callahan retweeted
Update on histone H3 copper reductase activity: Purified native yeast nucleosomes also act as enzymes & optimal activity depends on Zn. This could explain known Zn, Cu interplay & raises the possibility that DNA may be involved in electron conductance. 1/3
biorxiv.org/content/10.1101/…
Matt Callahan retweeted
“Fortune favors the prepared mind.” We @abu_remaileh and team serendipitously discover that CLN5, a genetic risk factor for Alzheimer’s disease, encodes the long-sought bis(monoacylglycero)phosphate synthase (BMPS) published in @ScienceMagazine. (1/11)
science.org/doi/10.1126/scie…
Matt Callahan retweeted
Designed Endocytosis-Triggering Proteins mediate Targeted Degradation and amplify signaling biorxiv.org/cgi/content/shor… #bioRxiv
There is a lot we still don’t understand about this system, but we end with a speculative model about how it may work. In short, we think that the balance of expression between CHIP partners, including chaperones & cochaperones, will dictate formation of the CHIC2/CHIP complex.
HUGE thanks to my collaborator Molly Hodul in @AimeeKaoLab, the crystallography team @ThePageLab, and @GestwickiLab members @proteins_Emma, @matthewravalin, & Cory Nadel, who were all instrumental in moving this project forward. This work would not have been possible without you!














